• Serve as lead and subject matter expert in Novartis TRD Cell & Gene therapy organization on iPSC-derived disease relevant cell model to support cell-based assay development for cell therapy (CAR-T and HSC).• Led and developed a platform ddPCR-based AAV infectivity assay to support AAV early process improvement. • Led and developed a 96-well ddPCR-based LVV mRNA potency/expression assay to support IND submission for autologous HSC cell therapy program. o Technical lead for assay and knowledge transfer to CRO for method qualification and subsequent release testing.o Lead method knowledge transfer to Novartis cell therapy analytics team to support the development of mRNA potency/expression for cell therapy final product.• Collaborated with Novartis NBC to support novel viral vector functionality assessment using high content imaging system. • Led and trained multiple team members on iPSC derived T cell model development from beginning to end.• Mentor and support one junior lab associates on career growth from execution focused analyst to taking on independent study design, execution, data analysis & interpretation.

• In-house development of normal Human iPSC derived 3D human organoid culture system, including culture medium, universal passage and frozen reagents. • Established Cancer patient tissue-derived lung organoid lines, used them for disease modeling, drug screen and RNASeq analysis. • Validated and developed application for hydrogel 3D 96-well microtiter plates for adipogenic differentiation from human mesenchymal stem cells. Products launched include: • Eight 3dGRO Human Lung Organoid lines from Non-small cell lung cancer (NSCLC) patients. • 3dGRO normal human iPSC derived Lung organoid culture system: human iPSC derived Anterior Foregut Endoderm progenitors as well as stepwise 3dGRO Lung organoid differentiation medium. human iPSC derived colon organoids. • TrueGel3D HTS Hydrogel Plate.

Developed Simplicon mRNA and STEMCCA Lenti-viral reprogramming kits to generate human and mouse induced pluripotent stem (iPS) cells from human and mouse somatic cells. Developed feeder-free and Xeno-free culture media that maintain human embryonic stem cells (hESCs) & iPS cells. Products launched:• Simplicon RNA Reprogramming Kit.• STEMCCA Cre-Excisable and Constitutive Polycistronic (OKSM) Lentivirus Reprogramming Kit.• PluriStem and PluriSTEM-XF human ES/iPS medium, a serum-free or Xeno-free & feeder-free medium for hESCs culture. • TAT-CRE recombinant protein. • Supervise Scientist II and Scientist I.

Control of mesodermal differentiation of human embryonic stem cells (hESCs). • Evaluated the long-term and multi-lineage in vivo reconstituting ability of hESC-derived hematopoietic cells in immunodeficient mice.• Participated in Affymetrix chips and Serial analysis of gene expression (SAGE) to identify early changes in gene expression that correlate with loss of pluripotency of hESCs in various cell lines.Identified genes maintaining the pluripotency of mouse embryonic stem cells (mESCs). • Identified genes that play important roles in maintaining viability and pluripotency of mESCs.• Elucidated the effects of key signaling pathway that controls related gene expression.

Investigated lineage differentiation of mouse hematopoietic stem cells.• Designed and developed a new clonal analysis covering myeloid, erythroid, T and B cell lineages to investigate the developmental potential of single individual cells in various subpopulations of mouse fetal liver (FL), fetal thymus (FT) or AGM cells, which enabled illustrating the framework of the early stages of lineage commitment in fetal hematopoiesis.• Discovered difference in the differentiation and proliferation potential of T cell progenitors between adult and fetal thymuses and characterized the early progenitors in adult thymus.• Supervise Master course college student and undergraduate students.